These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3709959)

  • 21. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Zeiler HJ
    Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of the effect of new fluoroderivatives of piperazinol-quinoline on clinical strains of aerobic and anaerobic bacteria].
    Dzierzanowska D; Ukraiński W; Piotrowska E; Kazmirowska Z; Pykiel M
    Pol Tyg Lek; 1986 Sep; 41(37):1180-3. PubMed ID: 3822880
    [No Abstract]   [Full Text] [Related]  

  • 24. In-vitro activity of norfloxacin against Enterobacteriaceae and Pseudomonas aeruginosa.
    García-Rodríguez JA; Gómez-García AC; Rodrigo N
    J Antimicrob Chemother; 1984 Aug; 14(2):192-3. PubMed ID: 6238928
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Nitrofurans: a modern treatment for uncomplicated urinary infections?].
    Cahen P; Honderlick P
    Pathol Biol (Paris); 2000 Jun; 48(5):470-1. PubMed ID: 10949843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Study of the sensitivity to pipemidic acid, pefloxacin and norfloxacin of 444 bacterial strains isolated at a general hospital].
    Berardi-Grassias LD; Roy O
    Pathol Biol (Paris); 1987 May; 35(5):467-72. PubMed ID: 3112705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of norfloxacin on bacterial flora in human feces].
    Motohiro T; Oda K; Aramaki M; Kawakami A; Tanaka K; Koga T; Shimada Y; Tomita S; Sakata Y; Fujimoto T
    Jpn J Antibiot; 1987 Sep; 40(9):1584-616. PubMed ID: 3694785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity.
    Goldstein EJ
    Am J Med; 1987 Jun; 82(6B):3-17. PubMed ID: 3111257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of pH, inoculum and media on the in vitro bactericidal activity of fosfomycin trometamol, norfloxacin and cotrimoxazole.
    Albini E; Belluco G; Marca G
    Chemioterapia; 1986 Aug; 5(4):268-72. PubMed ID: 3533286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice.
    Membrez M; Blancher F; Jaquet M; Bibiloni R; Cani PD; Burcelin RG; Corthesy I; Macé K; Chou CJ
    FASEB J; 2008 Jul; 22(7):2416-26. PubMed ID: 18326786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients.
    Leigh DA; Smith EC; Marriner J
    J Antimicrob Chemother; 1984 May; 13 Suppl B():79-83. PubMed ID: 6234279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility testing of urinary tract pathogens to norfloxacin.
    Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Aug; 28(2):309-11. PubMed ID: 1778861
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections.
    Boerema JB; Olthof BJ; van Saene HK
    Scand J Infect Dis Suppl; 1986; 48():27-31. PubMed ID: 3095916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro activity of norfloxacin alone and in combination].
    Ferrara A; Alessandrini R; Grassi FA; Gialdroni Grassi G
    G Ital Chemioter; 1985; 32(3):531-8. PubMed ID: 3836903
    [No Abstract]   [Full Text] [Related]  

  • 37. [Susceptibility to norfloxacin of some bacterial strains causing urinary infections].
    Tuchiluş C; Poiată A; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):383-6. PubMed ID: 16607805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical studies of norfloxacin in urinary tract infections].
    Matsuura T; Kurita T
    Hinyokika Kiyo; 1985 Nov; 31(11):2085-9. PubMed ID: 4091145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of ciprofloxacin against resistant clinical isolates.
    Kelley SG; Bertram MA; Young LS
    J Antimicrob Chemother; 1986 Mar; 17(3):281-6. PubMed ID: 2939048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Norfloxacin resistant Neisseria gonorrhoeae in North America.
    Yeung KH; Dillon JR
    Lancet; 1990 Sep; 336(8717):759. PubMed ID: 1975937
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.